News

Tirzepatide and AOD-9604 vs. Retatrutide for St...

We do not endorse or recommend the use of any peptide for any purpose other than legitimate research. Stubborn belly fat remains a focus of metabolic

AOD-9604 and CJC-1295 Stack for Targeted Abdomi...

This is general educational content. Personal health decisions should involve a qualified clinician familiar with your medical history. Research interest in ...

Tirzepatide vs. Retatrutide After FDA Panel Vote

An FDA panel vote on tirzepatide's weight-loss indication has intensified comparisons with retatrutide. This article examines published research on their

Tirzepatide Compounded GLP-1 Safety After FDA W...

The FDA's 2024 warning on compounded tirzepatide raises safety concerns. This article reviews the regulatory context, industry response, and what

AOD-9604 Purity Concerns After Troubling GLP-1 ...

Recent findings of impurities in compounded tirzepatide raise concerns about AOD-9604 purity. This article examines the research implications, analytical

AOD-9604 Safety Amid GLP-1 Compounding Pharmacy...

Compounding pharmacy violations raise safety concerns for peptides like AOD-9604. Research data is sparse, with no significant weight loss